title: TAXUS Liberté attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program.
abstract: OBJECTIVE
  The aim of this study was to assess the relative efficacy and safety of the second-generation TAXUS Liberté paclitaxel-eluting stent (PES) in patients with and without diabetes mellitus.
  
  
  BACKGROUND
  Diabetic patients suffer from accelerated atherosclerosis and increased risk of restenosis after coronary interventions; however, prior data suggest that PES might blunt this effect, providing equal benefit in diabetic and nondiabetic patients.
  
  
  METHODS
  A pooled analysis of all 4 TAXUS ATLAS studies was conducted that included 413 diabetic and 1,116 nondiabetic subjects treated with the TAXUS Liberté stent for de novo coronary lesions. Angiographic and intravascular ultrasound outcomes at 9 months and clinical outcomes at 9 and 12 months were compared in patients with and without diabetes. Propensity score and multivariate adjustments were performed to correct for baseline differences.
  
  
  RESULTS
  In-stent angiographic restenosis (13.0% vs. 9.6%, p = 0.12), late luminal loss (0.40 mm vs. 0.38 mm, p = 0.58), and intimal hyperplasia (14.8% vs. 13.4%, p = 0.29) were similar for diabetic and nondiabetic subjects. After propensity adjustment, 12-month target lesion revascularization rates were similar for diabetic and nondiabetic subjects (6.4% vs. 4.7%, p = 0.18), with no differences in mortality, myocardial infarction, or stent thrombosis. However, the rate of target vessel revascularization (TVR) was higher for diabetic subjects due to increased TVR outside the target lesion (TVR Remote).
  
  
  CONCLUSIONS
  Similar clinical, angiographic, and intravascular ultrasound outcomes were observed for both diabetic and nondiabetic subjects treated with TAXUS Liberté, suggesting that this PES attenuates the effect of diabetes on restenosis after percutaneous coronary intervention, yielding comparable efficacy and safety in diabetic and nondiabetic patients. (TAXUS ATLAS; NCT00371709, NCT00371423, NCT00371748, and NCT00371475).
authors.affiliation: University of California, San Diego, California 92103-8784, USA. emahmud@ucsd.edu
authors.forename: Ehtisham
authors.initials: E
authors.lastname: Mahmud
authors.forename: John A
authors.initials: JA
authors.lastname: Ormiston
authors.forename: Mark A
authors.initials: MA
authors.lastname: Turco
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Popma
authors.forename: Neil J
authors.initials: NJ
authors.lastname: Weissman
authors.forename: Charles D
authors.initials: CD
authors.lastname: O'Shaughnessy
authors.forename: Tift
authors.initials: T
authors.lastname: Mann
authors.forename: Jack J
authors.initials: JJ
authors.lastname: Hall
authors.forename: Thomas F
authors.initials: TF
authors.lastname: McGarry
authors.forename: Louis A
authors.initials: LA
authors.lastname: Cannon
authors.forename: Mark W I
authors.initials: MW
authors.lastname: Webster
authors.forename: Lazar
authors.initials: L
authors.lastname: Mandinov
authors.forename: Donald S
authors.initials: DS
authors.lastname: Baim
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use; D016022:Case-Control Studies; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control / Q000628:therapy*; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000628:therapy; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D018084:Ultrasonography, Interventional
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel